As new interventions for cognitive decline emerge, patients and providers need practical ways to determine whether therapy is working. James Hamet, founder of Vistim Labs, will discuss emerging approaches to monitoring changes in brain function over time, including the limitations of conventional imaging for frequent, repeated assessment. He will introduce Ceregram, Vistim Labs' AI-enabled, radiation-free approach that uses evoked-potential EEG data (the company's proprietary Evoked Potential Tomography, or EPT) to generate detailed measures of cognitive and neurological change. Vistim's published research reports strong correlations between Ceregram metrics and gold-standard biomarkers, including amyloid-PET SUVR and plasma p-tau181.
← All Discussion Rounds